Does managed care fuel pharmaceutical industry growth?

PharmacoEconomics

Volumn 14, Issue 4, 1998, Pages 341-348

  Murray, Michael D ^a,b   Deardorff, Frank W ^c  

^a PURDUE UNIVERSITY   (United States)

^b REGENSTRIEF INSTITUTE   (United States)

^c New Business Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIRHEUMATIC AGENT; ANTIULCER AGENT; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN DERIVATIVE; CETIRIZINE; CLARITHROMYCIN; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUOXETINE; GENERIC DRUG; HYPOCHOLESTEROLEMIC AGENT; NABUMETONE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; OXAPROZIN; RANITIDINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; SUMATRIPTAN;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; MANAGED CARE ORGANIZATION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED STATES;

DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; HEALTH EXPENDITURES; HUMANS; MANAGED CARE PROGRAMS; UNITED STATES;

EID: 0031695075     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814040-00001     Document Type: Review

References (28)

1. Kucukarslan S. In search of an understanding of pharmaceutical prices. J Res Pharm Econ 1996; 7: 73-88
2. Cohen KR. Managed competition: implications for the US pharmaceutical industry. J Res Pharm Econ 1996; 7: 29-40
3. Cockburn J, Pits S. Prescribing behaviour in clinical practice: patients expectations and doctors perceptions of patients expectations: a questionnaire study. BMJ 1997; 315: 520-3
4. Grol R. Beliefs and evidence in changing clinical practice. BMJ 1997; 315: 418-21
5. US Department of Health and Human Services. Press release. 13 January 1998
6. Miller RH, Luft HS. Does managed care lead to better or worse quality care? Health Aff 1997; 16: 7-25
7. Anderson GF. In search of value: an international comparison of cost, access, and outcomes. Health Aff 1997; 16(6): 163-71
8. Schondelmeyer SW, Thomas J, Trends in retail prescription expenditures. Health Aff 1990; 9: 131-45
9. Pryor D. A prescription for higher drug prices. Health Aff 1990; 9: 101-9
10. Moran DW. Federal regulation of managed care: an impulse in search of a theory? Health Aff 1997; 16: 7-21
11. Congress of the United States. Congressional Budget Office. How health care reform affects pharmaceutical research and development? Washington, DC: Congressional Budget Office, 1994
12. Ciba-Geigy Corporation. Pharmacy benefit report: HMO facts & figures. New Jersey: Ciba-Geigy Corporation, 1993
13. Hoechst Marion Roussel. Managed Care Digest Series™. Kansas City: Hoechst Marion Roussel, 1997
14. Chernew M, Fendrick M, Hirth RA. Managed care and medical technology: implications for cost growth. Health Aff 1997; 16: 196-206
15. Navarro RP. Regulation of pharmaceutical prices: a managed care perspective. Pharmacoeconomics 1993; 3: 179-82
16. Pollard MR. Managed care and a changing pharmaceutical industry. Health Aff 1990; 9: 55-65
17. Bobula JD. A new era in pharmaceutical pricing. J Res Pharm Econ 1996; 7: 89-99
18. Managed care spurs industry growth. Scrip 1997; 2226: 14
19. Wagner JL. Payment policy procedures and the health care consumer: weighing quality and cost decisions. J Res Pharm Econ 1994; 8: 51-63
20. Last years drug sales boom due to the effects of managed care: IMS America reports. Formulary 1997; 32: 667
21. Strategic Marketing Group (SMG) Inc. Chicago, 1997
22. Marketletter [via Newspage] 1998 Mar 19; 25
23. Schwartz RK, Soumerai SB, Avorn J. Physician motivations for nonscientific drug prescribing. Soc Sci Med 1989; 28: 577-82
24. Langley PC, Martin RE. Managed care guidelines for the economic evaluation of pharmaceuticals. Am J Manag Care 1997; 3: 1013-21
25. Stewart JH. Marketing to managed care institutions. Drug Inf J 1989; 23: 641-5
26. Clouse J. The effect of methodological advances in health economics on the marketplace. Drug Inf J 1995; 29: 1429-30
27. Draugalis JR, Coons SJ. Pharmacoeconomic research - facilitating collaboration among academic institutions, managed care organisations, and the pharmaceutical industry: a conference report. Clin Ther 1995; 17: 89-108
28. Epstein AM. The outcomes movement: will it get us where we want to go? N Engl J Med 1990; 323: 266-70